SDUY127
SDUY127 is a bivalent SHP2 inhibitor with an IC50 value of 16 nM. SDUY127 binds simultaneously to the tunnel allosteric site and latch allosteric site of SHP2 at a 1:1 stoichiometric ratio, stabilizes the protein in an inactive conformation, and induces sustained inhibition of the MAPK signaling pathway. SDUY127 can be used in research related to leukemia and hepatocellular carcinoma.
For research use only. We do not sell to patients.
- Formula: C58H69Cl2N13O9S
- Molecular Weight:1195.22
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
SDUY127 (1-3 μM; 48 h) inhibits MV4-11 leukemia cell proliferation by 33% at 1 μM and 79% at 3 μM after 48 h of treatment[1].
SDUY127 (10-30 μM; 48 h) inhibits Hep3B hepatocellular carcinoma cell proliferation by 23% at 10 μM and 84% at 30 μM after 48 h of treatment[1].
SDUY127 (3 μM; 15 min; 2 h) induces sustained suppression of ERK phosphorylation in MV4-11 cells, maintaining ~76% inhibition at 2 h post-treatment[1].
SDUY127 (3 μM; 15 min; 2 h) induces transient suppression of ERK phosphorylation in Hep3B cells, with inhibition decreasing from ~76% at 15 min to ~48% at 2 h post-treatment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MV4-11 leukemia cells
-
Concentration:3 μM
-
Incubation Time:15 min; 2 h
-
Result:Suppressed pERK levels by ~79% at 15 min.
Maintained pERK suppression at ~76% at 2 h.
-
Cell Line:Hep3B hepatocellular carcinoma cells
-
Concentration:3 μM
-
Incubation Time:15 min; 2 h
-
Result:Suppressed pERK levels by ~76% at 15 min.
Decreased pERK inhibition to ~48% at 2 h.
Chemical Information
-
Molecular Weight 1195.22
-
Formula C58H69Cl2N13O9S
-
SMILES
COC1=C(C=CC=C1C(N2C3=C4C=CC=C3)=NN=C2N(C4=O)CC5=CC=CC=C5Cl)OCCOCCOCCOCCN6CCN(CC6)C(CCCNC(CC(NC7=CC=CC(SC8=C(N)N=C(N9CCC(C)(CC9)N)C=N8)=C7Cl)=O)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
SDUY127 Related Classifications
HY-183936 Related Classifications
Powered by Bioz